ArticleThe oncologist2020
Diagnosis and Management of Rare Immune-Related Adverse Events.
Article in The oncologist, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 1 synthesis or guideline pooled it, 33 citations in OpenAlex.
- Multinational Association of Supportive Care in Cancer (MASCC) 2020 clinical practice recommendations for the management of severe gastrointestinal and hepatic toxicities from checkpoint inhibitors.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2020Guideline
- Development of Celiac Disease After Immunotherapy: A Case Series.Gastro hep advances · 2026Article
- Neuroimaging features of immune-related adverse events due to immune checkpoint inhibitor therapy.Insights into imaging · 2025Article
- Immune Checkpoint Inhibitor-Associated Celiac Disease: A Retrospective Analysis and Literature Review.Diseases (Basel, Switzerland) · 2024Review
- Combinatorial immune checkpoint blockade increases myocardial expression of NLRP-3 and secretion of H-FABP, NT-Pro-BNP, interleukin-1β and interleukin-6: biochemical implications in cardio-immuno-oncology.Frontiers in cardiovascular medicine · 2024Article
- Rare immune-related adverse events in patients with melanoma: incidence, spectrum, and clinical presentations.Oncoimmunology · 2023Article
- Histological Features of Celiac-Disease-like Conditions Related to Immune Checkpoint Inhibitors Therapy: A Signal to Keep in Mind for Pathologists.Diagnostics (Basel, Switzerland) · 2022Review
- Immune Checkpoint Inhibitor-Induced Central Diabetes Insipidus: Looking for the Needle in the Haystack or a Very Rare Side-Effect to Promptly Diagnose?Frontiers in oncology · 2022Review
- Clinical Characteristics and Outcomes of Patients with Positive Celiac Serology and Cancer Therapy Exposure.Journal of Cancer · 2022Article
- Grading Central Diabetes Insipidus Induced by Immune Checkpoint Inhibitors: A Challenging Task.Frontiers in endocrinology · 2022Review
- Small bowel villous atrophy due to immune-checkpoint inhibitors: report of two cases and literature review.Drugs in context · 2022Article
- Giant cell arteritis associated with PD-1 inhibition.BMJ case reports · 2021Article
- Targeted Cancer Therapy and Its Ophthalmic Side Effects: A Review.Journal of immunotherapy and precision oncology · 2021Review
- Identification and Classification of Polymyalgia Rheumatica (PMR) and PMR-Like Syndromes Following Immune Checkpoint Inhibitors (ICIs) Therapy: Discussion Points and Grey Areas Emerging from a Systematic Review of Published Literature.Medicines (Basel, Switzerland) · 2020Review
- Lessons to be Learnt from Real-World Studies on Immune-Related Adverse Events with Checkpoint Inhibitors: A Clinical Perspective from Pharmacovigilance.Targeted oncology · 2020Review
- Immune checkpoint inhibitor-associated celiac disease.Journal for immunotherapy of cancer · 2020Article
- Gastrointestinal and Hepatic Complications of Immunotherapy: Current Management and Future Perspectives.Current gastroenterology reports · 2020Review
- Bilateral Posterior Uveitis and Retinal Detachment During Immunotherapy: A Case Report and Literature Review.Frontiers in oncology · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Oncologic treatment is being revolutionized by a burgeoning number of immune checkpoint inhibitors (ICPis). To date, seven ICPis have received Food and Drug Administration approval, targeting cytotoxic T-lymphocyte antigen, programmed cell death, or programmed cell death ligand. Adverse events associated with checkpoint inhibition have been described in the literature. Guidelines exist for the most common of these, but as the use of ICPis becomes more common, the number of patients presenting with rare events will increase. This article reviews the diagnosis and management of rare ocular, hematological, luminal gastrointestinal, and rheumatological toxicities arising from ICPi treatment. KEY POINTS: As the use of immune checkpoint inhibitors (ICPis) becomes more common, the number of rare immune-related adverse events (irAEs) will increase. A high level of suspicion is required to identify and treat these toxicities. Although it can be difficult to definitively attribute rare irAEs to ICPis, a temporal and mechanistic relationship and the absence of other etiologies should make the treating physician suspicious for a rare irAE. Certain rare irAEs, such as celiac disease, do not require treatment with glucocorticoids. Thus, differentiating this irAE from other gastrointestinal irAEs has important implications for treatment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.